Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
Hereditary hyperekplexia, or startle disease, is a neuromotor disorder caused mainly by mutations that either prevent the surface expression of, or modify the function of, the human heteromeric α1 β glycine receptor (GlyR) chloride channel. There is as yet no explanation as to why hyperekplexia mutations that modify channel function are almost exclusively located in the α1 to the exclusion of β subunit. The majority of these mutations are identified in the M2-M3 loop of the α1 subunit. Here we demonstrate that α1 β GlyR channel function is less sensitive to hyperekplexia-mimicking mutations introduced into the M2-M3 loop of the β than into the α1 subunit. This suggests that the M2-M3 loop of the α subunit dominates the β subunit in gating the α1 β GlyR channel. A further attempt to determine the possible mechanism underlying this phenomenon by using the voltage-clamp fluorometry technique revealed that agonist-induced conformational changes in the β subunit M2-M3 loop were uncoupled from α1 β GlyR channel gating. This is in contrast to the α subunit, where the M2-M3 loop conformational changes were shown to be directly coupled to α1 β GlyR channel gating. Finally, based on analysis of α1 β chimeric receptors, we demonstrate that the structural components responsible for this are distributed throughout the β subunit, implying that the β subunit has evolved without the functional constraint of a normal gating pathway within it. Our study provides a possible explanation of why hereditary hyperekplexia-causing mutations that modify α1 β GlyR channel function are almost exclusively located in the α1 to the exclusion of the β subunit.
???displayArticle.pubmedLink???
22132222 ???displayArticle.pmcLink???PMC3222680 ???displayArticle.link???PLoS One
Figure 1. Distribution of hereditary hyperekplexia-causing mutations in the GlyR α1 and β subunits.The hereditary hyperekplexia-causing mutations that disrupt the GlyR channel function rather than block surface expression, are mapped onto the structure models [3] of GlyR α1 (A52S, E103K, R218Q, S231N, I244N, P250T, V260M, T265I, Q266H, S267N, R271L/Q, K276E and Y279C) and β (G229D) subunits.
Figure 2. Effects of M2–M3 loop mutations on α1 β GlyR channel function.(A) The positions where mutations were introduced, K24′, V25′ and Y27′, are shown in red in a structure model of the GlyR α1 subunit (left panel). Their positions are also indicated in the amino acid sequences of the M2–M3 loops of the α1 and β subunits (right panel). (B) Example traces of currents induced by increasing glycine concentrations in the indicated receptors. (C) Averaged normalized glycine concentration–response curves for the α1WT βWT GlyR (•),α1WT βK24′A GlyR (○) and the α1K24′A βWT GlyR (▾). (D) The RM/Ws (the EC50 of the mutant α1 β GlyR divided by the EC50 of the WT α1 β GlyR) resulting from introducing the K24′A, V25′A or Y27′A mutation into the α1 (•) and β (○) subunits are shown. (** p<0.01 using the Student's t-test).
Figure 3. VCF of α1 β GlyRs.Example current and fluorescence traces of the α19′C β and α β19′C GlyRs are shown in (A) and (C), respectively. Averaged normalized glycine concentration-response curves of current and fluorescence of the α19′Cβ and α β19′C GlyRs are shown in (B) and (D), respectively. The RF/Is (the EC50 of fluorescence divided by the EC50 of current) of the α19′C β and α β19′C GlyRs are plotted (E). (** p<0.01 using the Student's t-test).
Figure 4. Effects of M2–M3 loop mutations on chimeric α1 β GlyR channel function.(A) The molecular identity of each chimera is schematically illustrated, with green and red denoting α1 and β subunit sequences, respectively. (B–D) The RM/Ws (the EC50 of the mutant chimeric α1 β GlyR divided by the EC50 of its relevant WT chimeric α1 β GlyR) resulting from introducing the K24′A, V25′A or Y27′A mutation. The symbol (○) represents constructs containing WT α1 and mutant β or other indicated chimeric subunit, while the symbol (•) represents constructs containing mutant α1 and WT β or other indicated chimeric subunit. (* p<0.05; ** p<0.01; n.s.d. not significantly different; using the Student's t-test).
Figure 5. VCF of chimeric α1 β GlyRs.Averaged, normalized glycine concentration-response curves of current and fluorescence of α α-β19′C and α β-α19′C GlyRs are shown in (A) and (B), respectively. (C) The RF/Is (the EC50 of fluorescence divided by the EC50 of current) of the α19′C β, α β19′C, α α-β19′C, α β-α19′C, α αB-β19′C and α αT-β19′C GlyRs are plotted. (* p<0.05; ** p<0.01; n.s.d. not significantly different, using the Student's t-test).
Beato,
The activation mechanism of alpha1 homomeric glycine receptors.
2004, Pubmed
Beato,
The activation mechanism of alpha1 homomeric glycine receptors.
2004,
Pubmed Bocquet,
X-ray structure of a pentameric ligand-gated ion channel in an apparently open conformation.
2009,
Pubmed Bouzat,
Coupling of agonist binding to channel gating in an ACh-binding protein linked to an ion channel.
2004,
Pubmed Breitinger,
The inhibitory glycine receptor-simple views of a complicated channel.
2002,
Pubmed Brejc,
Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors.
2001,
Pubmed Burzomato,
Single-channel behavior of heteromeric alpha1beta glycine receptors: an attempt to detect a conformational change before the channel opens.
2004,
Pubmed Chung,
Pathophysiological mechanisms of dominant and recessive GLRA1 mutations in hyperekplexia.
2010,
Pubmed Colquhoun,
Binding, gating, affinity and efficacy: the interpretation of structure-activity relationships for agonists and of the effects of mutating receptors.
1998,
Pubmed Dahan,
A fluorophore attached to nicotinic acetylcholine receptor beta M2 detects productive binding of agonist to the alpha delta site.
2004,
Pubmed
,
Xenbase Engel,
Sleuthing molecular targets for neurological diseases at the neuromuscular junction.
2003,
Pubmed Gandhi,
Shedding light on membrane proteins.
2005,
Pubmed Gentet,
Binding site stoichiometry and the effects of phosphorylation on human alpha1 homomeric glycine receptors.
2002,
Pubmed Grewer,
Investigation of the alpha(1)-glycine receptor channel-opening kinetics in the submillisecond time domain.
1999,
Pubmed Grosman,
Mapping the conformational wave of acetylcholine receptor channel gating.
2000,
Pubmed Grosman,
The extracellular linker of muscle acetylcholine receptor channels is a gating control element.
2000,
Pubmed Grudzinska,
The beta subunit determines the ligand binding properties of synaptic glycine receptors.
2005,
Pubmed Harvey,
The genetics of hyperekplexia: more than startle!
2008,
Pubmed Hilf,
X-ray structure of a prokaryotic pentameric ligand-gated ion channel.
2008,
Pubmed Hilf,
Structure of a potentially open state of a proton-activated pentameric ligand-gated ion channel.
2009,
Pubmed Kash,
Coupling of agonist binding to channel gating in the GABA(A) receptor.
2003,
Pubmed Lee,
Binding to gating transduction in nicotinic receptors: Cys-loop energetically couples to pre-M1 and M2-M3 regions.
2009,
Pubmed Le Novère,
The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences.
2002,
Pubmed Lewis,
Kinetic determinants of agonist action at the recombinant human glycine receptor.
2003,
Pubmed Lewis,
Properties of human glycine receptors containing the hyperekplexia mutation alpha1(K276E), expressed in Xenopus oocytes.
1998,
Pubmed
,
Xenbase Liman,
Subunit stoichiometry of a mammalian K+ channel determined by construction of multimeric cDNAs.
1992,
Pubmed
,
Xenbase Lummis,
Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel.
2005,
Pubmed Lynch,
Identification of intracellular and extracellular domains mediating signal transduction in the inhibitory glycine receptor chloride channel.
1997,
Pubmed Lynch,
Native glycine receptor subtypes and their physiological roles.
2009,
Pubmed Lynch,
The surface accessibility of the glycine receptor M2-M3 loop is increased in the channel open state.
2001,
Pubmed Lynch,
Molecular structure and function of the glycine receptor chloride channel.
2004,
Pubmed Macdonald,
GABA(A) receptor epilepsy mutations.
2004,
Pubmed Miller,
Binding, activation and modulation of Cys-loop receptors.
2010,
Pubmed Ortells,
Evolutionary history of the ligand-gated ion-channel superfamily of receptors.
1995,
Pubmed Pless,
Conformational variability of the glycine receptor M2 domain in response to activation by different agonists.
2007,
Pubmed
,
Xenbase Pless,
Illuminating the structure and function of Cys-loop receptors.
2008,
Pubmed Pribilla,
The atypical M2 segment of the beta subunit confers picrotoxinin resistance to inhibitory glycine receptor channels.
1992,
Pubmed Purohit,
A stepwise mechanism for acetylcholine receptor channel gating.
2007,
Pubmed Rayes,
Number and locations of agonist binding sites required to activate homomeric Cys-loop receptors.
2009,
Pubmed Shan,
Asymmetric contribution of alpha and beta subunits to the activation of alphabeta heteromeric glycine receptors.
2003,
Pubmed Shan,
Chimera construction using multiple-template-based sequential PCRs.
2010,
Pubmed Shan,
A single beta subunit M2 domain residue controls the picrotoxin sensitivity of alphabeta heteromeric glycine receptor chloride channels.
2001,
Pubmed Thompson,
The structural basis of function in Cys-loop receptors.
2010,
Pubmed Tsunoyama,
Evolution of nicotinic acetylcholine receptor subunits.
1998,
Pubmed Unwin,
Refined structure of the nicotinic acetylcholine receptor at 4A resolution.
2005,
Pubmed Vogel,
Mapping of disulfide bonds within the amino-terminal extracellular domain of the inhibitory glycine receptor.
2009,
Pubmed Wang,
Ligand- and subunit-specific conformational changes in the ligand-binding domain and the TM2-TM3 linker of {alpha}1 {beta}2 {gamma}2 GABAA receptors.
2010,
Pubmed
,
Xenbase Yifrach,
Energetics of pore opening in a voltage-gated K(+) channel.
2002,
Pubmed
,
Xenbase